anti-claudin18.2/anti-CD3 bispecific antibody AZD5863

{
  "id": "MLC-T-ONC-010501",
  "term": "anti-claudin18.2/anti-CD3 bispecific antibody AZD5863",
  "field": "Oncology and biomedicine",
  "definition": "An affinity-optimized T-cell engaging (TCE) and human bispecific antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18) and the human T-cell surface antigen CD3, with potential immunostimulatory and antineoplastic activities. Upon administration, anti-CLDN18.2/anti-CD3 bispecific antibody AZD5863 simultaneously targets and binds to both CLDN18.2-expressing tumor cells, with bivalent high affinity binding, and CD3-expressing T cells, with monovalent low affinity binding. This crosslinks CLDN18.2-expressing tumor cells and cytotoxic T lymphocytes (CTLs) and results in the activation and proliferation of T cells. This causes a CTL-mediated cell lysis of CLDN18.2-expressing tumor cells. Additionally, AZD5863 induces bystander killing of CLDN18.2-negative tumor cells. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa. The bivalent high-affinity binding to CLDN18.2 and monovalent low-affinity binding to CD3 of AZD5863 may reduce toxicities while optimizing specific anti-tumor activity.",
  "synonyms": [
    "anti-CLDN18.2/anti-CD3 bispecific antibody AZD5863",
    "CLDN18.2 x CD3 bispecific antibody AZD5863",
    "CLDN18.2xCD3 bispecific antibody AZD5863",
    "T-cell engager AZD5863",
    "TCE AZD5863"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-claudin18-2-anti-cd3-bispecific-antibody-azd5863/"
}